{"id":174094,"date":"2026-09-25T12:44:43","date_gmt":"2026-09-25T12:44:43","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/174094\/"},"modified":"2026-09-25T12:44:43","modified_gmt":"2026-09-25T12:44:43","slug":"nanexa-and-novo-enter-into-eur-1-165-billion-global-license-and-collaboration-agreement-for-long-acting-injectables","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/174094\/","title":{"rendered":"Nanexa and Novo enter into EUR 1.165 billion global license and collaboration agreement for long-acting injectables"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The agreement grants Novo a global exclusive license to Nanexa&#8217;s proprietary PharmaShell\u00ae atomic layer deposition (ALD) drug delivery technology platform for certain therapeutic peptide drugs in indications including obesity, type 2 diabetes and other cardiometabolic diseases.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The agreement includes up to five development programs and covers different administration-frequency profiles with monthly and quarterly administration as target profiles.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo will lead global development and commercialization, and Nanexa is eligible to receive upfront consideration and potential milestone payments totaling up to EUR 1.165 billion, including EUR 615 million in upfront payment and development and regulatory milestones. In addition, the agreement provides for low single-digit royalties on future product sales.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The collaboration brings together Nanexa&#8217;s ALD-based long-acting injectable drug delivery platform and Novo&#8217;s expertise in obesity and type 2 diabetes treatments.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">UPPSALA, Sweden, Sept. 25, 2026 \/PRNewswire\/ &#8212; Nanexa AB (publ) (&#8220;Nanexa&#8221;), a Swedish drug delivery platform company developing long-acting injectable drugs based on its proprietary PharmaShell\u00ae technology platform, today announces that it has entered into a global exclusive license and collaboration agreement with Novo Nordisk (&#8220;Novo&#8221;) for the use of the PharmaShell\u00ae technology platform for certain peptide-based drugs targeting obesity, type 2 diabetes and other cardiometabolic indications.  <\/p>\n<p>    <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/a9fa5ca19b2975931193cd5f60f6f513c8b621abd9078d50822f26d10ac44a6c\/lightyear_networkapi\/resizefit_w960%3Bquality_80%3Bformat_webp\/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Fcnwgroup.com%2F4588b0a259245203e9b4464a9c6d82fb.jpg\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Nanexa logo\" height=\"125\" width=\"400\" class=\"yf-1f8hkhu loader\"\/><\/a> Nanexa logo           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Under the agreement, Novo receives a global license to use Nanexa&#8217;s PharmaShell\u00ae technology platform in up to five development programs. The collaboration includes development of long-acting injectable formulations with different administration-frequency profiles, with monthly and quarterly administration as target profiles.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Nanexa is eligible to receive total payments of up to EUR 1.165 billion, including EUR 615 million in upfront payment and development and regulatory milestones. The remaining milestone payments are sales milestones. In addition, Nanexa is eligible to receive low single-digit royalties on global net sales of products developed under the agreement.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">&#8220;We are very excited about and proud of this license agreement with Novo and look forward to working with them to successfully develop products with less frequent dosing in obesity and type 2 diabetes indications. Following our license and option agreement with Moderna in 2025, this agreement further strengthens the external validation of PharmaShell\u00ae as a broadly applicable drug delivery platform and we believe this provides a strong foundation for expanding PharmaShell\u00ae into additional therapeutic areas and to selectively advance additional internal programs towards clinical proof of concept, allowing us to capture greater value from the breadth of the PharmaShell\u00ae platform,&#8221; said David Westberg, CEO of Nanexa.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">PharmaShell\u00ae is Nanexa&#8217;s proprietary atomic layer deposition (ALD)-based drug delivery platform, designed to enable controlled and sustained release of active pharmaceutical ingredients through an ultra-thin inorganic coating applied to individual drug particles. The collaboration is intended to support the development of differentiated long-acting injectable drugs with the potential to reduce dosing frequency and improve the treatment experience for people living with chronic metabolic or cardiovascular diseases.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">&#8220;With this agreement, Nanexa enters a new era of considerable financial strength, allowing us to significantly expand applications of our unique ALD technology to other therapeutic areas and giving us an opportunity to build a sustainable long-term business. It will also allow us to take new projects further in development before partnering which will generate financially very attractive potential future partner deals. While expanding, our focus will also firmly be on creating a very successful partnership with Novo,&#8221; said G\u00f6ran Ando, Chairman of Nanexa.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Learn more at <a href=\"https:\/\/nanexa.com\/\" data-ylk=\"slk:https%3A%2F%2Fnanexa.com%2F;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;https:\/\/nanexa.com\/&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">https:\/\/nanexa.com\/<\/a>  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">For more information: <a href=\"https:\/\/sg.finance.yahoo.com\/news\/mailto:richard.hayhurst@59north.bio\" data-ylk=\"slk:richard.hayhurst%4059north.bio;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;richard.hayhurst@59north.bio&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">richard.hayhurst@59north.bio<\/a>  <\/p>\n<p>   <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/5da8752803715b3646e3ea83507f52ed09376a0a93595142fe31e00352a7f311\/lightyear_networkapi\/resizefit_w960%3Bquality_80%3Bformat_webp\/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Fcnwgroup.com%2Fc274cd7dce5c50ee68549585676cdf7e.png\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Cision\" height=\"16\" width=\"16\" class=\"yf-1f8hkhu loader\"\/><\/a> Cision          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"> View original content to download multimedia:<a href=\"https:\/\/www.prnewswire.com\/news-releases\/nanexa-and-novo-enter-into-eur-1-165-billion-global-license-and-collaboration-agreement-for-long-acting-injectables-302890175.html\" data-ylk=\"slk:https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fnanexa-and-novo-enter-into-eur-1-165-billion-global-license-and-collaboration-agreement-for-long-acting-injectables-302890175.html;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;https:\/\/www.prnewswire.com\/news-releases\/nanexa-and-novo-enter-into-eur-1-165-billion-global-license-and-collaboration-agreement-for-long-acting-injectables-302890175.html&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">https:\/\/www.prnewswire.com\/news-releases\/nanexa-and-novo-enter-into-eur-1-165-billion-global-license-and-collaboration-agreement-for-long-acting-injectables-302890175.html<\/a>  <\/p>\n<p>   <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/e28228486e02545dcdfcf751f187f454fb1433249aa9fffab98b12cfd3af7ebb\/lightyear_networkapi\/resizefit_w960%3Bquality_80%3Bformat_webp\/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Fcnwgroup.com%2F1526840cc47ca34d6f9f177339f2da5f.png\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Cision\" height=\"16\" width=\"16\" class=\"yf-1f8hkhu loader\"\/><\/a> Cision          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"> View original content to download multimedia: <a href=\"http:\/\/www.newswire.ca\/en\/releases\/archive\/September2026\/25\/c4099.html\" data-ylk=\"slk:http%3A%2F%2Fwww.newswire.ca%2Fen%2Freleases%2Farchive%2FSeptember2026%2F25%2Fc4099.html;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;http:\/\/www.newswire.ca\/en\/releases\/archive\/September2026\/25\/c4099.html&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">http:\/\/www.newswire.ca\/en\/releases\/archive\/September2026\/25\/c4099.html<\/a>  <\/p>\n","protected":false},"excerpt":{"rendered":"The agreement grants Novo a global exclusive license to Nanexa&#8217;s proprietary PharmaShell\u00ae atomic layer deposition (ALD) drug delivery&hellip;\n","protected":false},"author":2,"featured_media":174095,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[80005,6611,5032,80008,16178,80007,71491,272,80006,2142,80009],"class_list":["post-174094","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-atomic-layer-deposition","tag-collaboration","tag-development","tag-development-programs","tag-drug-delivery","tag-global-development","tag-milestone-payments","tag-novo-nordisk","tag-technology-platform","tag-type-2-diabetes","tag-upfront-payment"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117331746306682831","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/174094","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=174094"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/174094\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/174095"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=174094"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=174094"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=174094"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}